Results 1 to 10 of about 141,545 (201)

DNA methyltransferase inhibitor exposure–response: Challenges and opportunities [PDF]

Clinical and Translational Science, 2023
Although DNA methyltransferase inhibitors (DNMTis), such as azacitidine and decitabine, are used extensively in the treatment of myelodysplastic syndromes and acute myeloid leukemia, there remain unanswered questions about DNMTi's mechanism of action and
Amanda B. Kagan, Dominique A. Garrison, Nicole M. Anders, Jonathan A. Webster, Sharyn D. Baker, Srinivasan Yegnasubramanian, Michelle A. Rudek   +6 more
doaj   +4 more sources

Recent progress in DNA methyltransferase inhibitors as anticancer agents

Frontiers in Pharmacology, 2022
DNA methylation mediated by DNA methyltransferase is an important epigenetic process that regulates gene expression in mammals, which plays a key role in silencing certain genes, such as tumor suppressor genes, in cancer, and it has become a promising ...
Zhixiong Zhang, Zhixiong Zhang, Guan Wang, Yuyan Li, Yuyan Li, Dongsheng Lei, Jin Xiang, Liang Ouyang, Liang Ouyang, Yanyan Wang, Yanyan Wang, Jinliang Yang   +11 more
doaj   +5 more sources

DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma [PDF]

BMC Medicine, 2022
Background At present, the extent and clinical relevance of epigenetic differences between upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB) remain largely unknown. Here, we conducted a study to describe the global DNA
Juan Li, Yuan Liang, Jian Fan, Chunru Xu, Bao Guan, Jianye Zhang, Bin Guo, Yue Shi, Ping Wang, Yezhen Tan, Qi Zhang, Changwei Yuan, Yucai Wu, Liqun Zhou, Weimin Ci, Xuesong Li   +15 more
doaj   +2 more sources

Antitumor Effect of Simvastatin in Combination With DNA Methyltransferase Inhibitor on Gastric Cancer via GSDME-Mediated Pyroptosis [PDF]

Frontiers in Pharmacology, 2022
Gasdermin E (GSDME) is one of the executors of pyroptosis, a type of programmed lytic cell death, which can be triggered by caspase-3 activation upon stimulation.
Ying Xia, Ying Xia, Ying Xia, Ying Xia, Yong Jin, Yong Jin, Daxiang Cui, Xia Wu, Cunfeng Song, Weilin Jin, Weilin Jin, Hai Huang, Hai Huang   +12 more
doaj   +2 more sources

SGI-110: DNA Methyltransferase Inhibitor Oncolytic. [PDF]

Drugs Future, 2013
SGI-110 is a second-generation hypomethylating prodrug whose active metabolite is the well-characterized drug decitabine. This novel compound is an oligonucleotide consisting of decitabine linked through a phosphodiester bond to the endogenous nucleoside deoxyguanosine.
Griffiths EA, Choy G, Redkar S, Taverna P, Azab M, Karpf AR.   +5 more
europepmc   +3 more sources

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming

Nature Communications, 2021
De novo DNA methylation has been associated with T cell exhaustion in cancer immunotherapy. Here the authors show that the pre-treatment of CD19 CAR-T cells with the DNA methyltransferase inhibitor decitabine limits exhaustion and confers enhanced ...
Yao Wang, Chuan Tong, Hanren Dai, Zhiqiang Wu, Xiao Han, Yelei Guo, Deyun Chen, Jianshu Wei, Dongdong Ti, Zongzhi Liu, Qian Mei, Xiang Li, Liang Dong, Jing Nie, Yajing Zhang, Weidong Han   +15 more
doaj   +1 more source

Role of DVC1 in repair of nitrogen mustard-induced DNA protein crosslink in human bronchial epithelial cells

陆军军医大学学报, 2023
Objective To investigate the effect of DNA damage protein targeting VCP (DVC1) in DNA protein crosslink repair induced by nitrogen mustard in human bronchial epithelial cells (16HBE). Methods DVC1 siRNA was used to interfere its expression in 16HBE. Then
CHENG Jin, YU Wenpei, YE Feng
doaj   +1 more source

The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors

Frontiers in Oncology, 2021
Identification of novel tumor-specific targets is important for the future development of immunotherapeutic strategies using genetically engineered T cells or vaccines.
Mie K. Jakobsen, Sofie Traynor, Mette Stæhr, Pascal G. Duijf, Pascal G. Duijf, Aaraby Y. Nielsen, Mikkel G. Terp, Christina B. Pedersen, Per Guldberg, Per Guldberg, Henrik J. Ditzel, Henrik J. Ditzel, Henrik J. Ditzel, Morten F. Gjerstorff, Morten F. Gjerstorff, Morten F. Gjerstorff   +15 more
doaj   +1 more source

Angiostatic activity of DNA methyltransferase inhibitors [PDF]

Molecular Cancer Therapeutics, 2006
AbstractInhibitors of DNA methyltransferases (DNMT) and histone deacetylases can reactivate epigenetically silenced tumor suppressor genes and thereby decrease tumor cell growth. Little, however, is known on the effects of these compounds in endothelial cell biology and tumor angiogenesis.
Hellebrekers, Debby M E I, Jair, Kam-Wing, Viré, Emmanuelle, Eguchi, Sayaka, Hoebers, Nicole T H, Fraga, Mario F, Esteller, Manel, Fuks, François, Baylin, Stephen B, van Engeland, Manon, Griffioen, Arjan W   +10 more
openaire   +3 more sources

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

Nature Communications, 2021
Mesenchymal stromal cells (MSCs) have been shown to support multiple myeloma (MM) development. Here, MSCs isolated from the bone marrow of MM patients are shown to have altered DNA methylation patterns and a methyltransferase inhibitor reverts MM ...
Antonio Garcia-Gomez, Tianlu Li, Carlos de la Calle-Fabregat, Javier Rodríguez-Ubreva, Laura Ciudad, Francesc Català-Moll, Gerard Godoy-Tena, Montserrat Martín-Sánchez, Laura San-Segundo, Sandra Muntión, Xabier Morales, Carlos Ortiz-de-Solórzano, Julen Oyarzabal, Edurne San José-Enériz, Manel Esteller, Xabier Agirre, Felipe Prosper, Mercedes Garayoa, Esteban Ballestar   +18 more
doaj   +1 more source